Bronchiectasis nursing: assessment, management, and NCLEX tips

Bronchiectasis is a chronic lung disease defined by permanent, abnormal dilation of the bronchi caused by repeated cycles of infection and inflammation. It affects an estimated 340,000 to 500,000 adults in the United States, with prevalence rising sharply in people over 65. Despite its clinical significance, bronchiectasis is frequently underdiagnosed — many patients carry labels of “recurrent bronchitis” or “chronic obstructive pulmonary disease” for years before the correct diagnosis is made. For nursing students, bronchiectasis represents a high-yield respiratory topic: it bridges pneumonia nursing, cystic fibrosis nursing, airway clearance physiology, and complex medication management. Understanding how airway structure is permanently altered — and what that means for daily nursing care — is the core of clinical competency with this condition.

Quick reference

Pathophysiology

Bronchiectasis develops through a self-perpetuating cycle that begins with a trigger — infection, inflammation, or mechanical obstruction — and ends with structural destruction of the bronchial wall.

The normal bronchial wall has three layers: mucosa, submucosa, and cartilage. The cartilage maintains airway caliber; the mucociliary escalator moves secretions upward and outward. When an initial injury (most often infection) damages the airway epithelium, mucociliary clearance fails. Bacteria that would normally be expelled instead colonize the airway. The immune response — neutrophils, proteases, inflammatory cytokines — damages the bronchial wall further rather than resolving the infection. Cartilage and elastic tissue are progressively destroyed. The bronchi dilate and lose their ability to contract, creating dead-space pockets where secretions pool and bacteria multiply.

This is the “vicious cycle” of bronchiectasis: infection drives inflammation, inflammation destroys airway structure, structural damage worsens mucus retention, and retained mucus sustains infection. Once established, this cycle is self-perpetuating and the airway dilation is irreversible.

Morphological types

Three morphological patterns are recognized on CT imaging, reflecting the severity and duration of airway damage:

• Cylindrical (tubular): Most common. Airways are uniformly dilated, with parallel walls. Mildest form; the airway diameter is consistently larger than the adjacent pulmonary artery — this mismatch is the basis of the signet ring sign.
• Varicose: Irregular, beaded dilation with alternating areas of constriction and widening. More severe than cylindrical.
• Cystic: Most severe. Airways form thin-walled cysts or cavities. Associated with significant functional impairment. Common in advanced cystic fibrosis-related bronchiectasis.

Distinction from COPD

Bronchiectasis produces irreversible airway dilation with structural wall destruction. COPD (chronic obstructive pulmonary disease) produces airflow obstruction and air trapping from small airway disease and emphysema — but does not cause structural dilation of the bronchi. Both diseases can produce obstructive spirometry patterns and chronic cough, but their underlying anatomy is distinct. See ARDS nursing for context on acute-on-chronic respiratory failure presentations that can complicate both conditions.

Causes and risk factors

Bronchiectasis is not a single disease — it is the endpoint of many different conditions that share a common pathway of airway injury. Identifying the underlying cause guides long-term management.

Post-infectious (most common worldwide)

Severe or recurrent respiratory infections are the most common precipitating cause globally:

• Tuberculosis (TB): TB-related bronchiectasis remains the most common cause in low- and middle-income countries. Upper-lobe predominance is characteristic.
• Pertussis: Whooping cough in childhood (and increasingly in unvaccinated adults) can cause sufficient airway damage to initiate the bronchiectasis cycle. See pertussis nursing for disease-specific nursing care.
• Nontuberculous mycobacteria (NTM): Particularly Mycobacterium avium complex (MAC). NTM can both cause bronchiectasis and colonize airways already damaged by other causes. Increasingly recognized in older women with a characteristic body habitus (scoliosis, pectus excavatum, mitral valve prolapse — “Lady Windermere syndrome”).
• Other severe pneumonias: Severe viral pneumonitis (measles, adenovirus), bacterial pneumonia with abscess formation, or childhood infections before vaccination.

Cystic fibrosis

Cystic fibrosis (CF) is the most common identifiable cause of bronchiectasis in children in developed countries. The CFTR mutation causes dehydrated airway secretions that cannot be cleared, initiating the infection-inflammation cycle from infancy. All CF patients develop bronchiectasis; cystic or varicose morphology indicates advanced disease. See cystic fibrosis nursing for comprehensive CF management.

Immunodeficiency

Impaired antibody-mediated immunity leaves the airways susceptible to recurrent bacterial infections:

• Common variable immunodeficiency (CVID): Most common symptomatic antibody deficiency in adults. Low IgG, IgA, and IgM. Recurrent sinopulmonary infections lead to bronchiectasis in 30–50% of patients. Treatment: intravenous immunoglobulin (IVIG) replacement, which reduces exacerbation frequency if started before significant damage has occurred.
• Hypogammaglobulinemia from other causes: Chronic lymphocytic leukemia, myeloma, immunosuppressive therapy.
• HIV: Secondary immunodeficiency allows recurrent opportunistic and bacterial pulmonary infections.

Primary ciliary dyskinesia (PCD)

An autosomal recessive disorder of ciliary structure or function. Cilia that beat abnormally or not at all cannot clear secretions — mucociliary transport fails from birth. Classically associated with situs inversus (Kartagener syndrome: bronchiectasis + situs inversus + sinusitis), though most PCD patients have normal organ arrangement. Suspect PCD in young patients with bronchiectasis plus recurrent sinusitis plus infertility (immotile sperm use the same ciliary mechanism).

Allergic bronchopulmonary aspergillosis (ABPA)

A hypersensitivity reaction to Aspergillus fumigatus antigens in the airways. Occurs primarily in patients with asthma or CF. The inflammatory response causes central (proximal) bronchiectasis — a pattern that distinguishes ABPA from most other causes. Diagnosis requires elevated IgE, Aspergillus-specific IgE and IgG, and compatible CT findings. Treatment includes systemic corticosteroids and antifungal agents (itraconazole, voriconazole).

Autoimmune diseases

Several systemic autoimmune conditions predispose to bronchiectasis through airway inflammation:

• Rheumatoid arthritis (RA): Bronchiectasis occurs in up to 30% of RA patients, independent of smoking or drug therapy. Can precede joint disease. See rheumatoid arthritis nursing for RA-specific management context.
• Sjögren’s syndrome: Lymphocytic infiltration of bronchial walls and reduced secretory function.
• Inflammatory bowel disease: Particularly ulcerative colitis — airway inflammation can mirror gut inflammation.

Clinical presentation

Bronchiectasis presents with a characteristic triad: chronic productive cough, purulent sputum, and recurrent respiratory infections. The pattern is typically present for years before diagnosis.

Cough and sputum

The cough of bronchiectasis is productive, persistent, and often worst in the morning — when secretions accumulated overnight are mobilized by positional change and movement. Sputum in bronchiectasis is classically described as having three layers when collected in a container and allowed to settle: a top layer of froth and mucus, a middle layer of turbid mucopurulent material, and a bottom layer of dense pus. This layered appearance distinguishes bronchiectasis sputum from the simpler mucoid secretions of asthma or early COPD.

Daily sputum volume greater than 30 mL is clinically significant — this quantity reflects substantial airway burden and is associated with worse outcomes. Document sputum volume, color, consistency, and odor at every assessment.

Hemoptysis

Blood-streaked sputum to frank hemoptysis occurs when inflamed bronchial wall blood vessels erode. Minor hemoptysis (blood streaks, small amounts mixed with sputum) is common in bronchiectasis. Massive hemoptysis — defined as greater than 300 mL in 24 hours, or any volume causing hemodynamic compromise or respiratory distress — is a medical emergency requiring immediate bronchoscopic or angiographic intervention.

Other signs and symptoms

• Dyspnea: Ranges from exertional limitation in early disease to resting dyspnea with advanced airflow obstruction
• Digital clubbing: Appears with long-standing disease and chronic hypoxia; reflects periosteal new bone formation driven by hypoxemia and inflammatory mediators
• Recurrent respiratory infections: Patients often describe multiple courses of antibiotics per year for “chest infections” — the history of recurrent treated infections that never fully resolve is a diagnostic red flag
• Crackles (crepitations): Coarse, wet crackles heard on auscultation, often bilateral and worse at bases; reflect secretion movement in dilated airways

Diagnosis

High-resolution CT (HRCT) chest

HRCT is the gold standard for diagnosing bronchiectasis. Plain chest X-ray is insensitive and frequently normal, particularly in early or mild disease — it should not be used to confirm or exclude bronchiectasis.

HRCT findings include:

• Signet ring sign: The pathognomonic CT finding. A dilated bronchus (the ring) appears adjacent to the smaller pulmonary artery (the diamond or stone) in cross-section. When the bronchial diameter exceeds the adjacent arterial diameter, the signet ring sign is present. In normal airways, bronchus and adjacent artery are approximately the same size.
• Tramlines: Parallel lines representing thickened, dilated bronchial walls seen longitudinally.
• String of cysts (cystic pattern): Clusters of thin-walled cystic spaces in the most severe morphological pattern.
• Mucus plugging: Tubular or branching high-density opacities (the “finger-in-glove” appearance) representing secretion-filled dilated bronchi.

Sputum culture

Sputum Gram stain and culture identifies colonizing organisms and guides antibiotic selection. Clinically important organisms include:

• Pseudomonas aeruginosa: The most clinically significant pathogen — associated with accelerated lung function decline, increased exacerbation frequency, and higher mortality. Once established, eradication is rarely achieved; suppression is the goal.
• Haemophilus influenzae: Most common bacterial isolate in non-CF bronchiectasis
• Staphylococcus aureus (including MRSA)
• Nontuberculous mycobacteria (NTM) — require acid-fast bacilli (AFB) staining and culture, which takes weeks

Pulmonary function tests (PFTs)

Spirometry typically shows an obstructive pattern: reduced FEV1 and FEV1/FVC ratio. Some patients have a mixed obstructive-restrictive pattern. Severity of airflow obstruction correlates with disease extent and is used to guide treatment intensity and transplant referral.

Sputum AFB × 3

Three consecutive early-morning sputum samples for AFB smear and culture are required to evaluate for NTM and tuberculosis. A single negative specimen is insufficient. Results take 6–8 weeks due to the slow growth of mycobacteria.

Additional testing for underlying cause

• Sweat chloride test (pilocarpine iontophoresis): rule out CF in patients under 40
• Serum immunoglobulins (IgG, IgA, IgM): screen for antibody deficiency
• Aspergillus IgE and total IgE: screen for ABPA in asthma or CF patients
• Autoimmune panel (RF, ANA, anti-CCP): screen for connective tissue disease
• Nasal nitric oxide: reduced in primary ciliary dyskinesia

Medical management

Airway clearance devices and techniques

Airway clearance is the cornerstone of bronchiectasis management — performed at least twice daily, every day, regardless of symptom level.

• Active cycle of breathing technique (ACBT): The gold standard physiotherapy technique. Consists of three phases repeated in cycles: (1) breathing control — relaxed tidal breathing at normal rate, (2) thoracic expansion exercises — slow, deep inspirations with optional breath hold at full inflation to collateral ventilate airways distal to secretion plugs, and (3) forced expiration technique (FET/huffing) — one or two huffs from mid-lung volume to move secretions centrally, followed by coughing to expectorate. ACBT can be performed without any equipment, making it practical for home use.
• Oscillating positive expiratory pressure (OPEP) devices: The Flutter, Acapella, and Aerobika devices create oscillating airflow during expiration. The oscillations thin secretions by vibration while the positive pressure splints airways open, preventing early airway closure during expiration. Preferred by many patients over ACBT because less technique-dependent.
• High-frequency chest wall oscillation (HFCWO/vest): Inflatable vest delivers rapid chest compressions to loosen mucus. Used primarily in CF but increasingly in non-CF bronchiectasis in patients with significant daily sputum burden.
• Postural drainage: Gravity-assisted positioning with the affected lung segment uppermost to drain secretions toward central airways. Used as an adjunct to ACBT or OPEP, particularly for lower lobe disease. Trendelenburg position (head-down) maximizes lower lobe drainage but is contraindicated in patients with gastroesophageal reflux disease.

Inhaled and nebulized therapies

Long-term antibiotic therapy

Long-term macrolide antibiotics are the most important pharmacological intervention for reducing exacerbation frequency in bronchiectasis with chronic Pseudomonas colonization or frequent exacerbations.

• Azithromycin 500 mg three times per week (or 250 mg daily): The primary agent. Its benefit is partly anti-inflammatory (suppresses neutrophil-driven inflammation, reduces cytokine release) and partly antibacterial. Reduces exacerbation frequency by approximately 30–40%. Monitor QTc before starting and periodically — azithromycin prolongs the QT interval. Check for Mycobacterium avium complex (MAC) before initiating — azithromycin monotherapy in unrecognized MAC infection can select for macrolide-resistant NTM, making subsequent treatment much harder.
• Inhaled antibiotics (tobramycin, colistin, aztreonam lysine): Considered for patients with confirmed Pseudomonas aeruginosa colonization who continue to exacerbate despite oral macrolide therapy. Deliver high antibiotic concentrations to the airway with minimal systemic absorption, reducing systemic toxicity.

Exacerbation management

A bronchiectasis exacerbation is defined by increased cough, change in sputum quantity or color, increased dyspnea, fatigue, fever, or falling oxygen saturation. Treatment is guided by sputum culture from the most recent clinic visit or from sputum collected at the time of the exacerbation:

• Mild exacerbation (ambulatory, stable): Oral antibiotics targeting the colonizing organism. For Pseudomonas: ciprofloxacin 500–750 mg twice daily for 14 days. For Haemophilus influenzae: amoxicillin-clavulanate or doxycycline.
• Severe exacerbation (hospitalized, systemic signs, declining SpO2): IV antibiotics. Anti-pseudomonal regimens include piperacillin-tazobactam, ceftazidime, meropenem, or tobramycin — often in combination. Duration: 14 days minimum.
• Never use antitussives during an exacerbation. Cough suppression in bronchiectasis prevents expectoration of infected secretions, worsening infection and obstruction.

Nursing assessment

Respiratory assessment

Monitor and document the following at every patient contact:

• Respiratory rate and pattern: Tachypnea (RR >20), use of accessory muscles (sternocleidomastoid, scalenes), pursed-lip breathing, paradoxical breathing
• SpO2: Baseline must be established for each patient — many chronic bronchiectasis patients have resting SpO2 of 92–95% and titrate oxygen accordingly. Target SpO2 ≥92% in most patients; exercise caution with supplemental oxygen in patients with known CO2 retention (type 2 respiratory failure risk)
• Auscultation: Coarse crepitations (crackles) — note location and whether they clear with coughing or huffing, which indicates they are in accessible airways. Wheeze if bronchospasm is present. Silence in a previously crackly region may indicate worsening obstruction — not clinical improvement.
• Work of breathing: Nasal flaring, intercostal and subcostal recession, tracheal tug. Severity of work of breathing is a more reliable distress indicator than RR alone.

Sputum assessment

Sputum is the primary clinical window into bronchiectasis disease activity:

• Color: Yellow-green or green sputum indicates bacterial infection or colonization. A change from baseline (e.g., clear to purulent) signals exacerbation.
• Consistency: Thick, tenacious sputum suggests inadequate hydration or suboptimal mucolytic therapy.
• Volume: Quantify in milliliters where possible. Increased daily volume from patient’s personal baseline is an exacerbation criterion. Greater than 30 mL/day is clinically significant.
• Odor: Foul-smelling sputum suggests anaerobic organisms or lung abscess.

Hemoptysis assessment

Distinguish between:

• Blood-streaking of sputum: Common; monitor volume and frequency; not immediately alarming in isolation
• Frank hemoptysis: Quantify (teaspoon, tablespoon, cup) — any escalation in amount requires immediate physician notification
• Massive hemoptysis: Greater than 300 mL in 24 hours, or any volume causing airway compromise, hemodynamic instability, or severe distress — medical emergency. Maintain airway. Position with the bleeding lung DEPENDENT (affected side down) to protect the unaffected lung. Prepare for bronchoscopy or bronchial artery embolization.

Systemic assessment

• Temperature and WBC: Fever and leukocytosis indicate active infection or exacerbation
• CRP/ESR: Elevated in active inflammation; useful for tracking treatment response during an exacerbation
• Sputum culture results: Review at every encounter — new organisms, particularly first isolation of Pseudomonas or NTM, change the management pathway
• Hydration status: Dehydrated patients produce thicker, harder-to-clear secretions. Assess mucous membranes, skin turgor, urine output, and intake.
• Mental status: Hypoxia and hypercapnia both cause altered consciousness — agitation or confusion in a bronchiectasis patient with respiratory compromise should prompt urgent ABG.
• Nutrition: Chronic respiratory disease increases caloric expenditure. Weight loss and poor nutrition worsen immune function and accelerate lung function decline.

Nursing interventions

Positioning for airway drainage

Position the patient to maximize gravitational drainage of affected lung segments toward the central airways:

• Upright sitting (Fowler’s or high Fowler’s): Default position for most patients — reduces work of breathing and promotes lower lobe drainage
• Postural drainage positions: Place the affected lung segment uppermost, using a tilted bed or positioning wedges. For lower lobe disease, a mild head-down tilt (modified Trendelenburg) promotes drainage. Avoid head-down positions in patients with active hemoptysis, uncontrolled GERD, raised intracranial pressure, or cardiovascular instability.

Airway clearance assistance

Teaching and supervising ACBT is a core nursing intervention:

1. Breathing control phase: Encourage slow, relaxed tidal breathing for 5–10 seconds. Emphasize shoulders down, abdominal breathing — prevent hyperventilation between active phases.
2. Thoracic expansion exercises: Three to four slow, deep inspirations to full lung capacity, with optional 2–3 second breath hold at full inflation (promotes collateral ventilation behind secretion plugs). Followed by passive, relaxed expiration — do not force.
3. Forced expiration technique (FET / huffing): One to two huffs from mid-lung volume — a forced but controlled expiration through an open mouth. Followed by a rest period of breathing control. Effective huffing moves secretions from peripheral to central airways; coughing then expels them. Teach the difference between a huff (sustained, controlled) and an explosive cough (less effective, more exhausting).

For patients using OPEP devices (Acapella, Flutter): coach on correct mouth seal, flow rate, and expiratory effort. An insufficient seal or incorrect angle (for Flutter device) negates the oscillation effect.

Medication administration and sequencing

The sequence of inhaled therapies matters:

1. Short-acting bronchodilator (albuterol) first — opens airways
2. Airway clearance session — ACBT or OPEP
3. Nebulized hypertonic saline — administered before the next airway clearance session to prime secretions if used twice daily, or sequenced as: bronchodilator → hypertonic saline → airway clearance for the most effective mucolytic priming

Administer IV antibiotics during exacerbations per culture and sensitivity results. Monitor tobramycin peak and trough levels if IV aminoglycosides are used. Assess for ototoxicity (tinnitus, hearing changes) and nephrotoxicity (rising creatinine, reduced urine output).

Hydration management

Systemic hydration thins respiratory secretions and maintains mucociliary transport function. Targets:

• Maintain urine output ≥0.5 mL/kg/hour
• Encourage oral fluid intake: at least 2–3 liters daily unless fluid restriction is clinically indicated
• IV fluid resuscitation during exacerbations if oral intake is inadequate
• Avoid dehydration during fever: increased insensible losses require increased replacement

Oxygen therapy

• Titrate supplemental oxygen to maintain SpO2 ≥92%
• In patients with known chronic hypercapnia or type 2 respiratory failure: target SpO2 88–92% to avoid suppressing hypoxic respiratory drive
• Monitor for CO2 retention if oxygen requirements increase — obtain arterial blood gas if respiratory effort appears to diminish despite improved SpO2
• Nasal cannula for maintenance oxygen; high-flow nasal cannula or non-invasive ventilation (NIV/BiPAP) for acute exacerbations with hypercapnia. See pulmonary embolism nursing for comparison of acute respiratory presentations requiring oxygen management decisions.

Hemoptysis emergency management

For massive hemoptysis (>300 mL/24h or hemodynamically significant):

1. Position: Immediately place the patient with the affected (bleeding) lung side DOWN. This prevents blood from flooding the contralateral (healthy) lung and causing aspiration and asphyxiation.
2. Airway: Maintain airway patency. Prepare for emergent intubation — large-volume hemoptysis can cause asphyxiation within minutes.
3. Hold airway clearance: Suspend all ACBT, chest physiotherapy, and postural drainage until the acute bleeding episode is managed.
4. Notify physician immediately: Bronchial artery embolization is the most effective acute intervention; rigid bronchoscopy provides airway control and can tamponade the bleeding source.
5. IV access, type and crossmatch, blood products: Initiate for volume replacement if hemodynamic compromise is present.

Infection control

• Standard precautions for all bronchiectasis patients
• Contact and droplet precautions when MRSA or Pseudomonas are confirmed
• Patients with NTM colonization (particularly M. abscessus) should not be cohorted in the same bay as cystic fibrosis patients — emerging evidence supports NTM patient-to-patient transmission between CF and non-CF bronchiectasis patients
• Dedicate nebulizer equipment to individual patients — shared nebulizer cups transmit organisms

Patient education

Key education priorities for discharge and ongoing management:

• Airway clearance technique: Demonstrate and return-demonstrate ACBT. Emphasize twice-daily practice as a lifelong commitment — not only during exacerbations. The analogy of “daily dental hygiene for the lungs” helps frame this as maintenance, not treatment.
• Recognizing exacerbations: Teach patients to monitor sputum color, volume changes, and respiratory symptom escalation. Action plan: who to call and when.
• Vaccinations: Annual influenza, pneumococcal vaccine (PCV15/PCV20 and PPSV23 per current schedule), and pertussis (Tdap booster if not up to date) — prevent the respiratory infections that trigger exacerbations.
• Smoking cessation: Smoking accelerates airway damage, worsens mucociliary function, and increases exacerbation frequency. Frame cessation as a clinical intervention, not a lifestyle choice. See drug classifications nursing for pharmacotherapy options including varenicline and bupropion.
• Hydration: Encourage consistent daily fluid intake as part of the airway clearance routine.
• Inhaler technique: Review device technique at every contact. Incorrect technique is extremely common and significantly reduces drug delivery.

Complications

NCLEX tips

NCLEX tip 1: HRCT is the gold standard — not plain CXR High-resolution CT (HRCT) chest is the gold standard diagnostic test for bronchiectasis. Plain chest X-ray is insensitive and frequently normal in early or mild disease. When an NCLEX question asks which test best confirms bronchiectasis, the answer is HRCT — not chest X-ray, not spirometry.

NCLEX tip 2: The signet ring sign is pathognomonic The signet ring sign on HRCT — a dilated bronchus with a diameter greater than the adjacent pulmonary artery, seen in cross-section — is the pathognomonic CT finding for bronchiectasis. The bronchus is normally the same size as its adjacent artery. If the bronchus is larger, bronchiectasis is present.

NCLEX tip 3: Antitussives are CONTRAINDICATED Never use cough suppressants (codeine, dextromethorphan, or any antitussive) in a patient with bronchiectasis. The productive cough is the body’s primary mechanism for clearing infected secretions from permanently dilated airways. Suppressing it causes secretion retention, worsening infection and obstruction. This is a high-priority safety principle and will appear on NCLEX.

NCLEX tip 4: Sputum volume >30 mL/day is clinically significant Daily sputum production exceeding 30 mL (roughly 2 tablespoons) is a threshold marker for significant airway burden in bronchiectasis. It is associated with worse outcomes, more frequent exacerbations, and more aggressive management requirements. Document and report changes in sputum volume.

NCLEX tip 5: Hemoptysis — position the affected lung down When a patient with bronchiectasis develops significant hemoptysis, position the patient with the bleeding lung (affected side) DEPENDENT — that is, placed downward. This prevents blood from flooding the intact contralateral lung. An NCLEX question may frame this as which position to place the patient: the bleeding lung goes down, not up.

NCLEX tip 6: Azithromycin is anti-inflammatory, not just antibiotic Long-term azithromycin (500 mg three times per week or 250 mg daily) in bronchiectasis works through anti-inflammatory and immunomodulatory mechanisms — not purely as an antibiotic. It suppresses neutrophil-driven airway inflammation and reduces exacerbation frequency by approximately 30–40%. Knowing that its benefit is partly independent of direct antibacterial activity explains why it is used in patients without active infection.

NCLEX tip 7: Check for NTM before starting azithromycin Before initiating long-term azithromycin, obtain sputum AFB cultures to exclude nontuberculous mycobacteria (NTM) infection. Azithromycin monotherapy in a patient with unrecognized NTM rapidly selects for macrolide-resistant organisms, severely limiting future treatment options. This sequence — rule out NTM first, then start macrolide — is a clinically important patient safety step.

NCLEX tip 8: CF is the most common cause in children (developed countries) In developed countries, cystic fibrosis is the most common identifiable cause of bronchiectasis in children and young adults. Post-infectious causes (TB, pertussis) dominate globally but are less common in the United States. For pediatric bronchiectasis NCLEX questions, CF should be the first diagnosis considered.

NCLEX tip 9: Pseudomonas aeruginosa = worst prognostic pathogen Pseudomonas aeruginosa colonization is associated with accelerated lung function decline, increased exacerbation frequency, increased hospitalization, and higher mortality in bronchiectasis. Once established, it cannot be eradicated — management aims at suppression. Identifying new Pseudomonas on culture is a clinical escalation point and should prompt reevaluation of the management plan.

NCLEX tip 10: Bronchiectasis vs. COPD — structural distinction Bronchiectasis = irreversible bronchial dilation with destruction of the bronchial wall. COPD = airflow obstruction from small airway disease and emphysema, without structural airway dilation. Both produce obstructive spirometry patterns and chronic cough. The key distinction: bronchiectasis involves dilated, structurally destroyed airways visible on CT; COPD does not. This distinction is tested in differential diagnosis questions and helps clarify why management differs — particularly around airway clearance, which is central to bronchiectasis but not to standard COPD management.

Summary: clinical priorities for bronchiectasis nursing

Bronchiectasis nursing is built on three pillars: consistent airway clearance, early recognition of exacerbations, and prevention of complications. Airway clearance — performed twice daily, every day — is not optional. A patient who performs ACBT reliably will have fewer exacerbations, less antibiotic exposure, and slower disease progression than one who relies on medications alone.

Sputum is your primary assessment tool. Color changes, volume increases, and new odor all signal developing exacerbation before systemic signs appear. Hemoptysis — especially any escalation in volume — requires immediate, structured response: position the patient with the bleeding lung down, hold airway clearance, and escalate to the medical team.

Long-term management centers on keeping colonizing organisms suppressed, avoiding new infections (vaccination, smoking cessation, inhaler technique), and maintaining the functional gains of daily airway clearance. The nurse who understands this disease well enough to teach it clearly — why secretions accumulate, why antitussives are harmful, why positioning matters during hemoptysis — provides care that directly alters patient outcomes.

For broader respiratory pharmacology context, see drug classifications nursing. For the most common pediatric cause driving bronchiectasis in young patients, see cystic fibrosis nursing. For acute-on-chronic respiratory failure, see ARDS nursing.

Nursing care plans for bronchiectasis

The five care plans below reflect the priority nursing diagnoses encountered in bronchiectasis. They are ordered from highest to lowest clinical urgency and are formatted to the NANDA-I structure: diagnosis label, related factors, defining characteristics, interventions with rationale, and measurable expected outcomes.

Ineffective airway clearance

Related to: Impaired mucociliary function secondary to permanent bronchial dilation and chronic bacterial colonization

As evidenced by: Copious purulent sputum production (often >30 mL/day), coarse crepitations on auscultation, ineffective cough, retained secretions, and reduced SpO2 from mucus plugging

Nursing interventions

Expected outcomes

• Patient performs ACBT or OPEP technique independently with correct technique by discharge
• Sputum volume decreases to baseline or below within 48–72 hours of exacerbation treatment
• Breath sounds clear or improve after each airway clearance session
• SpO2 maintains ≥92% at rest

Impaired gas exchange

Related to: Ventilation-perfusion (V/Q) mismatch from mucus plugging of dilated airways, airway obstruction, and chronic airway inflammation

As evidenced by: Reduced SpO2, tachypnea, use of accessory muscles, dyspnea at rest or on exertion, abnormal arterial blood gas values (hypoxemia ± hypercapnia), and digital clubbing with long-standing disease

Nursing interventions

Expected outcomes

• SpO2 maintains within individualized target range on prescribed oxygen flow
• ABG values stabilize with PaO2 ≥60 mmHg and pH ≥7.35 during exacerbation treatment
• Patient reports reduced dyspnea within 24–48 hours of treatment initiation
• Patient demonstrates no acute signs of CO2 narcosis (somnolence, confusion, respiratory depression)

Risk for infection

Related to: Chronic bacterial colonization of permanently dilated airways (particularly Pseudomonas aeruginosa, Haemophilus influenzae, Staphylococcus aureus, and nontuberculous mycobacteria), impaired mucociliary clearance, and recurrent antibiotic exposure promoting resistance

As evidenced by: (Risk diagnosis — defining characteristics not required; risk factors present include confirmed colonizing organisms on sputum culture, history of recurrent exacerbations, chronic purulent sputum, and chronic antibiotic use)

Nursing interventions

Expected outcomes

• Patient remains afebrile with WBC trending toward normal within 72 hours of antibiotic initiation
• Sputum culture sensitivities guide antibiotic selection for each exacerbation
• Patient verbalizes signs of exacerbation requiring medical contact (increased sputum purulence/volume, fever, worsening dyspnea)
• Patient is up to date on influenza and pneumococcal vaccinations before discharge

Activity intolerance

Related to: Chronic hypoxemia, dyspnea on exertion, generalized deconditioning from recurrent hospitalizations, and increased work of breathing from obstructed airways

As evidenced by: Report of fatigue with minimal exertion, dyspnea during activities of daily living (ADLs), reduced SpO2 with activity, tachycardia on minimal exertion, and reluctance or inability to complete self-care without rest periods

Nursing interventions

Expected outcomes

• Patient completes ADLs with SpO2 maintained ≥90% with or without supplemental oxygen
• Patient demonstrates understanding of energy conservation techniques and pacing before discharge
• Patient tolerates progressive ambulation with reduction in dyspnea score over 48–72 hours
• Patient is enrolled in or referred to a pulmonary rehabilitation program at discharge

Deficient knowledge

Related to: Lack of prior education on chronic airway clearance techniques, medication sequencing, exacerbation recognition, and long-term self-management requirements of bronchiectasis

As evidenced by: Inability to demonstrate correct ACBT or OPEP technique, inconsistent use of airway clearance therapy, delayed recognition of exacerbation signs, and questions about medication purpose or correct inhaler technique

Nursing interventions

Expected outcomes

• Patient correctly demonstrates ACBT technique before discharge without prompting
• Patient articulates correct medication sequencing (bronchodilator → airway clearance → hypertonic saline if prescribed)
• Patient identifies at least three exacerbation warning signs and states when to contact their provider
• Patient states they will perform airway clearance twice daily as an ongoing routine

Frequently asked questions

What are the priority nursing diagnoses for bronchiectasis?

The two highest-priority NANDA-I diagnoses for bronchiectasis are ineffective airway clearance and impaired gas exchange. Airway clearance takes precedence because chronically retained secretions drive the infection-inflammation cycle that underlies all bronchiectasis complications. Impaired gas exchange follows because V/Q mismatch from mucus plugging and airway obstruction threatens oxygenation. Risk for infection, activity intolerance, and deficient knowledge round out the priority care plan set.

How do nurses perform airway clearance for bronchiectasis patients?

Nurses teach and supervise the Active Cycle of Breathing Technique (ACBT), which cycles through three phases: breathing control (relaxed tidal breathing), thoracic expansion exercises (slow deep breaths with an optional breath hold), and forced expiration technique (huffing from mid-lung volume to move secretions centrally). Oscillating PEP devices (Aerobika, Acapella, Flutter) are an alternative and are often preferred by patients because they are less technique-dependent. Medication sequencing matters: give a bronchodilator first to open airways, then perform airway clearance, then nebulize hypertonic saline to prime secretions for the next session.

What are the signs of a bronchiectasis exacerbation?

A bronchiectasis exacerbation is identified by a change from the patient’s baseline in two or more of the following: increased sputum volume, increased sputum purulence (change from clear/white to yellow/green), increased dyspnea or wheeze, worsening fatigue, fever above 38°C, or a decrease in SpO2 from baseline. Sputum changes typically precede systemic signs by 24–48 hours, making daily sputum self-monitoring a key early warning tool.

Which bacteria commonly colonize bronchiectasis airways?

The most important colonizing organism is Pseudomonas aeruginosa, which is associated with accelerated lung function decline, more frequent exacerbations, and higher mortality. Haemophilus influenzae is the most common isolate overall in non-CF bronchiectasis. Staphylococcus aureus (including MRSA) occurs in CF-related and post-viral bronchiectasis. Nontuberculous mycobacteria (NTM) – particularly Mycobacterium avium complex (MAC) – are identified in a significant minority and require a completely different treatment approach, including AFB cultures before any macrolide is started.

What is the role of inhaled hypertonic saline in bronchiectasis?

Nebulized hypertonic saline (3–7%) works as an osmotic agent: the high salt concentration draws water into the airway surface liquid, rehydrating dehydrated mucus and reducing its viscosity. Thinner mucus moves more readily on the mucociliary escalator and is easier to expectorate during ACBT or OPEP sessions. It is given after a bronchodilator (albuterol) to prevent bronchospasm, and before the airway clearance session it is intended to prime. Note that dornase alfa (DNase, Pulmozyme) is indicated only in cystic fibrosis–related bronchiectasis; it is not recommended for idiopathic or non-CF bronchiectasis.

How does bronchiectasis differ from COPD in nursing management?

The key structural difference is that bronchiectasis involves irreversible dilation and wall destruction of the conducting airways, while COPD involves small airway disease and emphysema without bronchial dilation. This distinction drives different priorities in nursing management: airway clearance (ACBT, OPEP, postural drainage) is central and daily for bronchiectasis because secretion retention is the primary driver of disease progression, while COPD management focuses primarily on bronchodilation and smoking cessation. Antitussives are contraindicated in bronchiectasis but not a concern in COPD, and long-term macrolide antibiotics are used in bronchiectasis but not in standard COPD therapy.

What positions help bronchiectasis patients clear secretions?

High Fowler’s position (45–90° upright) is the default for breathing comfort and reducing work of breathing. For gravity-assisted postural drainage, the affected lung segment is positioned uppermost so secretions drain toward central airways. For lower lobe disease, a mild head-down tilt (modified Trendelenburg) enhances drainage. During a massive hemoptysis event, the position reverses: the bleeding lung is placed dependent (affected side down) to protect the healthy lung from blood aspiration. Head-down positioning is contraindicated in patients with active hemoptysis, uncontrolled GERD, raised intracranial pressure, or cardiovascular instability.

What medications are used in bronchiectasis nursing care?

Key medication categories and nursing priorities: short-acting bronchodilators (albuterol) – given before every airway clearance session; inhaled hypertonic saline (3–7%) – given after bronchodilator to hydrate mucus; long-term azithromycin (500 mg three times per week or 250 mg daily) – anti-inflammatory and antibacterial, monitor QTc and rule out NTM before starting; antibiotics during exacerbations – culture-guided, ciprofloxacin for oral anti-pseudomonal coverage, IV piperacillin-tazobactam or meropenem for severe exacerbations; inhaled tobramycin or colistin – for confirmed Pseudomonas colonization with ongoing exacerbations despite oral macrolide. Antitussives are absolutely contraindicated in all bronchiectasis patients.

Clinical content reviewed against: BTS (British Thoracic Society) Bronchiectasis Guidelines 2019; ERS (European Respiratory Society) Bronchiectasis Guidelines 2017 and 2024 updates; NIH MedlinePlus bronchiectasis reference; NCBI/PubMed bronchiectasis pathophysiology, NTM, and Pseudomonas outcomes literature. All clinical thresholds and drug information reflect current evidence-based practice.